Sulindac sulfide differentially induces apoptosis in Smac-proficient and -deficient human colon cancer cells

Molecular and Cellular Pharmacology

Volumn 1, Issue 2, 2009, Pages 92-97

  Shi, Jingxue ^a   He, Qin ^a   An, Jie ^a   Sun, Hong ^a   Huang, Ying ^a   Sheikh, M Saeed ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Colon cancer; Death receptor 5; NSAIDs; Smac; Sulindac sulfide

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR 5; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; UPREGULATION;

INTRACISTERNAL A-PARTICLES;

EID: 75149187497     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.09.11     Document Type: Article

References (29)

1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-15.
2. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002;42:55-80.
3. Thun MJ, Namboodiri MM, Heath CJ Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
4. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
5. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 1999;159:161-6.
6. Thun, MJ, Henley SJ, Patrono C. Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. J Natl Cancer Inst 2002;94:252-66.
7. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116: 4-15.
8. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
9. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-73.
10. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
11. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
12. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995;75:936-8.
13. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis [letter]. Lancet 1993;342:1120.
14. Lim JT, Piazza GA, Han EK, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol 58: 1097-1107, 1999.
15. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-86.
16. Shiff SJ, Qiao L, Tsai L-L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
17. Huang Y, He Q, Hillman MJ, Huang Y, Sheikh M.S. Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells. Cancer Res 2001;61:6918-24.
18. Zhang L, Yu J, Park BH, Kinzler K W, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290:989-92.
19. He Q, Luo X, Huang Y and Sheikh MS. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002;21:6032-40.
20. Kohli M, Yu J, Seaman C, et al. SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci USA 2004;101:16897-902.
21. Du C, Fang M, Li Y, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
22. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
23. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000;406:855-62.
24. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004;29:486-94.
25. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008-12.
26. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000;408:1004-8.
27. He Q, Shi JX, Jones S, et al. Smac deficiency affects endoplasmic reticulum stress-induced apoptosis in human colon cancer cells. Mol Cell Pharmacol 2009;1:23-28.
28. He Q, Lee DI, Rong R, et al. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 2002;21:2623-33.
29. Askkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.